GB201510684D0 - Gene signatures predictive of metastatic disease - Google Patents

Gene signatures predictive of metastatic disease

Info

Publication number
GB201510684D0
GB201510684D0 GBGB1510684.2A GB201510684A GB201510684D0 GB 201510684 D0 GB201510684 D0 GB 201510684D0 GB 201510684 A GB201510684 A GB 201510684A GB 201510684 D0 GB201510684 D0 GB 201510684D0
Authority
GB
United Kingdom
Prior art keywords
metastatic disease
gene signatures
signatures predictive
predictive
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1510684.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Almac Diagnostics Ltd
Original Assignee
Almac Diagnostics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almac Diagnostics Ltd filed Critical Almac Diagnostics Ltd
Priority to GBGB1510684.2A priority Critical patent/GB201510684D0/en
Publication of GB201510684D0 publication Critical patent/GB201510684D0/en
Priority to CA2989388A priority patent/CA2989388A1/en
Priority to HK18105968.7A priority patent/HK1246367A1/zh
Priority to CN201680045157.3A priority patent/CN108513587A/zh
Priority to JP2017565108A priority patent/JP2018527886A/ja
Priority to EP16731299.0A priority patent/EP3310927B1/en
Priority to US15/736,667 priority patent/US20210254166A1/en
Priority to PCT/GB2016/051825 priority patent/WO2016203262A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GBGB1510684.2A 2015-06-17 2015-06-17 Gene signatures predictive of metastatic disease Ceased GB201510684D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB1510684.2A GB201510684D0 (en) 2015-06-17 2015-06-17 Gene signatures predictive of metastatic disease
CA2989388A CA2989388A1 (en) 2015-06-17 2016-06-17 Gene signatures predictive of metastatic disease
HK18105968.7A HK1246367A1 (zh) 2015-06-17 2016-06-17 转移性疾病的基因标记预测
CN201680045157.3A CN108513587A (zh) 2015-06-17 2016-06-17 对转移性疾病具有预测性的基因标签
JP2017565108A JP2018527886A (ja) 2015-06-17 2016-06-17 転移性疾患の予測的遺伝子シグネチャー
EP16731299.0A EP3310927B1 (en) 2015-06-17 2016-06-17 Gene signatures predictive of metastatic disease
US15/736,667 US20210254166A1 (en) 2015-06-17 2016-06-17 Gene signatures predictive of metastatic disease
PCT/GB2016/051825 WO2016203262A2 (en) 2015-06-17 2016-06-17 Gene signatures predictive of metastatic disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1510684.2A GB201510684D0 (en) 2015-06-17 2015-06-17 Gene signatures predictive of metastatic disease

Publications (1)

Publication Number Publication Date
GB201510684D0 true GB201510684D0 (en) 2015-08-05

Family

ID=53784091

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1510684.2A Ceased GB201510684D0 (en) 2015-06-17 2015-06-17 Gene signatures predictive of metastatic disease

Country Status (8)

Country Link
US (1) US20210254166A1 (enExample)
EP (1) EP3310927B1 (enExample)
JP (1) JP2018527886A (enExample)
CN (1) CN108513587A (enExample)
CA (1) CA2989388A1 (enExample)
GB (1) GB201510684D0 (enExample)
HK (1) HK1246367A1 (enExample)
WO (1) WO2016203262A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11341138B2 (en) * 2017-12-06 2022-05-24 International Business Machines Corporation Method and system for query performance prediction
GB201901439D0 (en) * 2019-02-01 2019-03-27 Univ London Method of predicting survival rates for cancer patients
GB201903015D0 (en) * 2019-03-08 2019-04-17 Univ Edinburgh Macrophage expression in breast cancer
GB201903014D0 (en) * 2019-03-06 2019-04-17 Univ Edinburgh Macrophage markers in cancer
JP7741104B2 (ja) * 2020-01-21 2025-09-17 ジェニアリス インコーポレイテッド 分子バイオマーカーデータセット全体にわたる予測シグネチャの堅牢性および転用可能性の評価
CA3174199A1 (en) 2020-04-09 2021-10-14 Ashraf Hafez Predicting likelihood and site of metastasis from patient records
TW202216996A (zh) 2020-06-29 2022-05-01 美商Ionis製藥公司 調節ｐｌｐ１之化合物及方法
WO2022086914A1 (en) * 2020-10-19 2022-04-28 Temple University - Of The Commonwealth System Of Higher Education Genetic approach to suppress coronaviruses
CN117741155A (zh) * 2023-11-21 2024-03-22 中国药科大学 Abcc4蛋白用于制备前列腺癌诊断试剂盒的用途
CN120197220B (zh) * 2025-05-23 2025-08-01 华信咨询设计研究院有限公司 一种基于数据集中度的数据风险评估方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4437975A (en) 1977-07-20 1984-03-20 Mobil Oil Corporation Manufacture of lube base stock oil
IE72468B1 (en) 1987-07-31 1997-04-09 Univ Leland Stanford Junior Selective amplification of target polynucleotide sequences
ZA899593B (en) 1988-12-16 1990-09-26 Siska Diagnostics Inc Self-sustained,sequence replication system
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
EP1474528A4 (en) * 2000-10-13 2006-06-14 Protein Design Labs Inc METHODS OF DIAGNOSIS OF PROSTATE CANCER, COMPOSITIONS AND METHODS OF EXAMINING PROSTATE CANCER MODULATORS
WO2004067726A2 (en) 2003-01-29 2004-08-12 Keck Graduate Institute Isothermal reactions for the amplification of oligonucleotides
WO2004085621A2 (en) * 2003-03-20 2004-10-07 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
JP2008518610A (ja) 2004-11-03 2008-06-05 アルマック ダイアグノスティックス リミテッド トランスクリプトームマイクロアレイ技法およびそれを使用する方法
US20140018249A1 (en) * 2006-07-26 2014-01-16 Health Discovery Corporation Biomarkers for screening, predicting, and monitoring benign prostate hyperplasia
NZ582941A (en) 2007-08-13 2012-05-25 Almac Diagnostics Ltd A 3' -based sequencing approach for microarray manufacture
DK2376215T3 (en) * 2008-12-11 2019-01-28 Univ California FILTER CONE
CA2782620A1 (en) * 2009-12-01 2011-06-09 Compendia Bioscience, Inc. Classification of cancers
CA2836277A1 (en) * 2011-05-17 2012-11-22 Takeda Pharmaceutical Company Limited Pharmaceutical compositions and methods for treating cancer
WO2014012176A1 (en) * 2012-07-20 2014-01-23 Diagnocure Inc. Methods, kits and compositions for providing a clinical assessment of prostate cancer

Also Published As

Publication number Publication date
US20210254166A1 (en) 2021-08-19
HK1246367A1 (zh) 2018-09-07
WO2016203262A2 (en) 2016-12-22
CA2989388A1 (en) 2016-12-22
JP2018527886A (ja) 2018-09-27
EP3310927B1 (en) 2021-05-19
EP3310927A2 (en) 2018-04-25
CN108513587A (zh) 2018-09-07
WO2016203262A3 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
IL255729A (en) Methods for predicting pathogenicity of variant gene sequences
ZA201701246B (en) Synthesis of dna
ZA201701916B (en) High-throughput nucleotide library sequencing
ZA201802462B (en) Gene therapy
SMT202100520T1 (it) Costrutto genico
SG11201610168YA (en) Nucleic acid synthesis techniques
GB201805452D0 (en) Predicting disease burden from genome variants
LT3662910T (lt) Trail geno indukcijai skirtas farmakoforas
IL255515A (en) Identification of genetic changes
GB201517022D0 (en) No details
GB201507104D0 (en) Nucleic acid construct
GB201407322D0 (en) Gene therapy
IL257831A (en) Diplospore garden
IL249254B (en) Gene expression system
IL257500A (en) Altered cullin1 gene
GB201517241D0 (en) DNA modification
GB201614153D0 (en) Microfluid arrangements
SG11201609108TA (en) Antibody gene expression-secretion system
GB201608944D0 (en) Gene Tharapy
SG10201912789UA (en) Determination of mtrnr1 gene mutation
GB201503969D0 (en) Reporter gene assay
AU2014901825A0 (en) Biomarker of Disease
AU2016901024A0 (en) Biomarker of disease
GB201704466D0 (en) Behavioural assay
GB201506520D0 (en) Planar member formation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)